Liver Ablative Radiotherapy utilizing Kilovoltage intrafraction monitoring (KIM)

Stereotactic Ablative Body Radiotherapy (SABR) is an established treatment for both primary and secondary liver malignancies and is a highly effective treatment, but precise dose delivery is challenging due to organ motion. Currently, there is a lack of widely available options for performing real-time tumour localisation to assist with accurate delivery of liver SABR. This study will provide an assessment of the impact of Kilovoltage Intrafraction Monitoring (KIM) as a potential solution for real-time image guidance in liver SABR. It is hoped that this information will improve cancer targeting accuracy and lead to better patient outcomes in the future.

Primary Sponsor

University of Sydney

Collaborating Groups

TROG Cancer Research

Accrual Target

46

Closing Date of Accrual

11 December 2023

Trial Chairperson

Dr Yoo Young (Dominique) Lee, Princess Alexandra Hospital, QLD
Dr Tim Wang, Crown Princess Mary Cancer Centre, Westmead, NSW

Trial Contact

LARK@trog.com.au

Clinical Trial Registration

Related Post

David, Jasmine and Susan Goode, re Kokoda Challenge to support TROG Cancer Research
27 May, 2025

Intrepid trekkers to take on Kokoda Challenge for TROG

LATEST NEWS: 27 May 2025 A team of five

Clinical Trials Day 2025 stand at Calvary Mater Newcastle
27 May, 2025

Clinical Trials Day celebrations help spread the work about TROG’s work

LATEST NEWS: 27 MAY 2025 TROG members and staff